38 / 60
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 1, January/February 2021
36
AFRICA
Relationship between physical activity and carotid intima–media thickness among teachers in
South Africa: the SABPA study
by Tamrin Veldsman, Mariette Swanepoel, Andries Monyeki, Sanette
Brits, Leoné Malan, published in the
Cardiovascular Journal of Africa
2020;
31
(6): 304–318.
DOI: 10.5830/CVJA-2020-024
In the Abstract, in Methods:
Ultrasound CIMT imaging was done using the SonoSite
Micromaxx. Physical activity was done over seven consecutive
days.
In the Abstract, in Results:
The prevalence of obesity according to BMI and sedentary
behaviour was above 30%; hypertension was 38.9% and low-grade
inflammation (CRP) was 41.1%.
Erratum
7.
Santoro G, Meucci F, Stolcova M, Rezzaghi M, Mori F, Palmieri C,
et al
.
Percutaneous left atrial appendage occlusion in patients with non-valvu-
lar atrial fibrillation: implantation and up to four years follow-up of the
AMPLATZER Cardiac Plug.
EuroIntervention
2016;
11
: 1188–1194.
8.
Landmesser U, Tondo C, Camm J, Diener H-C, Paul V, Schmidt B,
et al
.
Left atrial appendage occlusion with the AMPLATZER Amulet device:
one-year follow-up from the prospective global Amulet observational
registry.
EuroIntervention
2018;
14
: e590–e597
9.
Lee E, Choi E-K, Han K-D, Lee H, Choe WS, Lee S-R,
et al
. Mortality
and causes of death in patients with atrial fibrillation: A nationwide
population-based study.
PLoS One
2018;
13
(12): e0209687.
10. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy
D. Impact of atrial fibrillation on the risk of death: the Framingham
Heart Study.
Circulation
1998;
98
(10): 946–952.
11. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA.
Atrial fibrillation and risks of cardiovascular disease, renal disease, and
death: systematic review and meta-analysis.
Br Med J
2016;
354
: i4482.
12. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality
in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study
of Atrial Fibrillation (SCAF).
Eur Heart J
2007;
28
(19): 2346–2353.
13. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM,
Edvardsson N,
et al
. All-cause mortality in 272,186 patients hospitalized
with incident atrial fibrillation 1995–2008: a Swedish nationwide long-
term case-control study.
Eur Heart J
2013;
34
(14): 1061–1067.
14. Dukkipati SR, Kar S, Holmes DR, Doshi SK, Swarup V, Gibson DN,
et
al
. Device-related thrombus after left atrial appendage closure: incidence,
predictors, and outcomes.
Circulation
2018;
138
(9): 874–885.
15. Alkhouli M, Busu T, Shah K, Osman M, Alqahtani F, Raybuck B.
Incidence and clinical impact of device-related thrombus following
percutaneous left atrial appendage occlusion: a meta-analysis.
J Am Coll
Cardiol Clin Electrophysiol
2018;
4
: 1629–1637.
16. Osmancik P, Tousek P, Herman D, Neuzil P, Hala P, Stasek J,
et al.
;
PRAGUE-17 investigators. Interventional left atrial appendage closure
vs novel anticoagulation agents in patients with atrial fibrillation indi-
cated for long-term anticoagulation (PRAGUE-17 study).
Am Heart J
2017;
183
: 108–114.
17. Godino C, Melillo F, Bellini B, Mazzucca M, Pivato CA, Rubino F,
et
al.
Percutaneous left atrial appendage closure versus non-vitamin K oral
anticoagulants in patients with non-valvular atrial fibrillation and high
bleeding risk
. EuroIntervention
2020;
15
: 1548–1554.